NSE: GLAND | BSE: 543245

Strong Performer, Getting Expensive

Download real time

2213.10 -49.10 (-2.17%)

40.64% Gain from 52W Low

595.8K NSE+BSE Volume

NSE 15 Jun, 2026 3:31 PM (IST)

36,507.2

Market Cap

High in industry

Beta 1Year

Very Low volatility

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

22 May 2026

2213.10

-2.17%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in...

Number of FII/FPI investors decreased from 236 to 230 in Mar 2026 qtr

Gland Pharma Ltd.

29 Jan 2026

2213.10

-2.17%

Result Update:Gland Pharma

Buy: Gland Pharma Ltd.

Recommendation

Axis Direct

We maintain our BUY rating on the stock.

Gland Pharma Ltd. has an average target of 2288.33 from 3 brokers.

Gland Pharma Ltd.

29 Jan 2026

2213.10

-2.17%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

Gland Pharma has gained 32.54% in the last 6 Months

Gland Pharma Ltd.

28 Jan 2026

2213.10

-2.17%

Cenexi break-even/US uptrend drives earnings beat

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered better-than-expected 3QFY26 financial performance with a 6%/14%/19% beat on revenue/EBITDA/PAT.

Gland Pharma Ltd. has an average target of 2288.33 from 3 brokers.

Gland Pharma Ltd.

04 Nov 2025

2213.10

-2.17%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We revise our rating from HOLD to BUY

Gland Pharma has gained 18.46% in the last 1 Month

Gland Pharma Ltd.

04 Nov 2025

2213.10

-2.17%

Gland Pharma

Buy: Gland Pharma Ltd.

ICICI Direct

Gland Pharma has gained 32.54% in the last 6 Months

Gland Pharma Ltd.

04 Nov 2025

2213.10

-2.17%

In-line revenue; margin miss transient

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lowerthan-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance.